These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 7831676)

  • 1. Cost effectiveness and ease of administration of low molecular weight heparin in deep vein thrombosis.
    Teo CP; Lim HL; Kueh YK
    Thromb Haemost; 1994 Aug; 72(2):328-9. PubMed ID: 7831676
    [No Abstract]   [Full Text] [Related]  

  • 2. [Evaluation of hospital cost of six days of treatment of deep venous thrombosis. Comparison of subcutaneous nadroparin and intravenous heparin in 40 patients].
    Lévesque H; Cailleux N; Vasse D; Legallicier B; Moore N; Borg JY; Hantute N; Thuillez C; Courtois H
    Therapie; 1994; 49(2):101-5. PubMed ID: 7817331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of the use of nadroparin in the treatment of deep-vein thrombosis in Switzerland.
    Lloyd AC; Aitken JA; Hoffmeyer UK; Kelso EJ; Wakerly EC; Barber ND
    Ann Pharmacother; 1997; 31(7-8):842-6. PubMed ID: 9220041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Low molecular weight heparins. No increase of the cost of treatment of deep venous thrombosis].
    Levesque H; Cailleux N; Courtois H
    Presse Med; 1994 Apr 30-May 7; 23(17):816. PubMed ID: 8078843
    [No Abstract]   [Full Text] [Related]  

  • 5. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective.
    Hull RD; Raskob GE; Pineo GF; Feldstein W; Rosenbloom D; Gafni A; Green D; Feinglass J; Trowbridge AA; Elliott CG
    Arch Intern Med; 1997 Feb; 157(3):298-303. PubMed ID: 9040296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemostatic activation under anticoagulant treatment: a comparison of unfractionated heparin vs. nadroparin in the treatment of proximal deep vein thrombosis.
    Stricker H; Marchetti O; Haeberli A; Mombelli G
    Thromb Haemost; 1999 Oct; 82(4):1227-31. PubMed ID: 10544903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. FRAXODI group.
    Charbonnier BA; Fiessinger JN; Banga JD; Wenzel E; d'Azemar P; Sagnard L
    Thromb Haemost; 1998 May; 79(5):897-901. PubMed ID: 9609216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary prophylaxis with low molecular weight heparin: the dose?
    Horne MK
    Thromb Haemost; 2001 Oct; 86(4):1129. PubMed ID: 11686343
    [No Abstract]   [Full Text] [Related]  

  • 9. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis.
    Simonneau G; Charbonnier B; Decousus H; Planchon B; Ninet J; Sie P; Silsiguen M; Combe S
    Arch Intern Med; 1993 Jul; 153(13):1541-6. PubMed ID: 8391792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the cost-effectiveness of administering heparin subcutaneously or intravenously for the treatment of deep vein thrombosis.
    Barber ND; Hoffmeyer UK
    Ann R Coll Surg Engl; 1993 Nov; 75(6):430-3. PubMed ID: 8285546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin).
    Mismetti P; Laporte-Simitsidis S; Navarro C; Sié P; d'Azemar P; Necciari J; Duret JP; Gaud C; Decousus H; Boneu B
    Thromb Haemost; 1998 Jun; 79(6):1162-5. PubMed ID: 9657442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ambulatory treatment without complications. A 1-year experience in distal deep-vein thrombosis].
    Svensson P; Lethagen S; Lindén E; Berntorp E
    Lakartidningen; 1994 Aug; 91(34):2950-2. PubMed ID: 7990537
    [No Abstract]   [Full Text] [Related]  

  • 13. [Health care economics evaluation of inpatient treatment of venous thrombosis with unfractionated heparin versus subcutaneous low molecular weight heparin at home].
    Osterkorn D; Schramm W; Szucs T
    Med Klin (Munich); 1996 Sep; 91(9):607-9. PubMed ID: 8984321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapy of thromboses with low-molecular-weight heparins].
    Haas S; Haas P
    Wien Med Wochenschr; 1999; 149(2-4):39-45; discussion 45. PubMed ID: 10378321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis.
    Rodger M; Bredeson C; Wells PS; Beck J; Kearns B; Huebsch LB
    CMAJ; 1998 Oct; 159(8):931-8. PubMed ID: 9834718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of iliofemoral thrombosis in a pregnant patient with heparin resistance.
    Anand SS; Brimble S; Ginsberg JS
    Arch Intern Med; 1997 Apr; 157(7):815-6. PubMed ID: 9125015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of ambulatory and inpatient treatment of acute deep venous thrombosis of the leg: subjective and economic aspects].
    Frank D; Blättler W
    Schweiz Med Wochenschr; 1998 Sep; 128(36):1328-33. PubMed ID: 9784675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial.
    Mismetti P; Mille D; Laporte S; Charlet V; Buchmüller-Cordier A; Jacquin JP; Fournel P; Dutrey-Dupagne C; Decousus H;
    Haematologica; 2003 Jan; 88(1):67-73. PubMed ID: 12551829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cost-effectiveness analysis of alternative approaches for long-term treatment of proximal venous thrombosis.
    Hull RD; Raskob GE; Hirsh J; Sackett DL
    JAMA; 1984 Jul; 252(2):235-9. PubMed ID: 6427492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective.
    Hull RD; Raskob GE; Rosenbloom D; Pineo GF; Lerner RG; Gafni A; Trowbridge AA; Elliott CG; Green D; Feinglass J
    Arch Intern Med; 1997 Feb; 157(3):289-94. PubMed ID: 9040295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.